secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0001628280-25-009233
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Solutions Q4 revenue $22.7M (+31% YoY); guides 2025 up 16-20%
---------------------------------------------------------------------

- Q4 total revenue $22.7M (up 31% YoY); Cell Processing $20.3M (+37% YoY).
- GAAP net loss from continuing ops $2.0M vs $7.2M YoY; adjusted EBITDA $4.0M (18% of revenue).
- Completed sales of SciSafe and CBS in Nov 2024 for ~$79.1M total cash; cash and marketable securities $109.2M.
- 2025 revenue guidance $95.5-99.0M (growth 16-20%); Cell Processing $86.5-89.0M (growth 18-21%).
- Cumulative 769 FDA Master File cross-references; biopreservation media in 17 approved cell/gene therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828025009233/0001628280-25-009233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828025009233/blfs-20250303.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-009233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer